Tesamorelin vs Sermorelin

Comparison

Tesamorelin and Sermorelin are two peptides people frequently compare. Tesamorelin is the active ingredient in Egrifta, an FDA-approved treatment for excess belly fat in people with HIV-associated lipodystrophy. It works by stimulating the pituitary to release growth… Sermorelin is a peptide people use to stimulate natural growth hormone release for aging-related GH decline, body composition, and recovery. It works by activating the same pituitary receptor as the…

	Tesamorelin	Sermorelin
What it is	Tesamorelin is the active ingredient in Egrifta, an FDA-approved treatment for excess belly fat in people with HIV-associated lipodystrophy. It works by stimulating the pituitary to release growth…	Sermorelin is a peptide people use to stimulate natural growth hormone release for aging-related GH decline, body composition, and recovery. It works by activating the same pituitary receptor as the…
Primary uses	HIV-associated lipodystrophy / excess visceral abdominal fat in people with HIV HIV-associated non-alcoholic fatty liver disease (NAFLD) / metabolic dysfunction-associated steatotic liver disease (MASLD) Body composition improvement (visceral fat, lean mass, muscle quality) in people with HIV Metabolic effects: triglycerides, inflammatory markers, cardiovascular risk markers	Growth hormone secretagogue — raising serum IGF-1 in hypogonadal men on testosterone therapy Diagnostic / physiological probe for GH secretion assessment Sports / athletic performance enhancement (off-label, unapproved use) Musculoskeletal injury recovery / orthopaedic adjunct (proposed, largely preclinical)
How it works	It works by stimulating the pituitary to release growth hormone, which reduces visceral fat. Prescription-only for that indication; also being studied for cognitive function and fatty liver in HIV…	It works by activating the same pituitary receptor as the natural hormone that triggers GH pulses. Previously FDA-approved; now only available through compounding; banned by WADA in sport.
Common dose	2000 mcg, subcutaneous injection, once daily	200-300 mcg, subcutaneous injection, daily, before bed
FDA status	Approved by the US Food and Drug Administration in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Described as the only FDA-approved therapy to…	Not stated in reviewed literature — requires manual verification
Evidence level	Human RCT	Human RCT
	Full Tesamorelin page →	Full Sermorelin page →

Ask about Tesamorelin vs Sermorelin in chat →